Skip to main content
Erschienen in: Der Pathologe 1/2008

01.02.2008 | Schwerpunkt: Leberpathologie

Hepatozelluläre Karzinome in der nichtzirrhotischen Leber

verfasst von: M. Evert, Prof. Dr. F. Dombrowski

Erschienen in: Die Pathologie | Ausgabe 1/2008

Einloggen, um Zugang zu erhalten

Zusammenfassung

Das hepatozelluläre Karzinom (HCC) entsteht zu etwa 15–20% in nichtzirrhotischen Lebern. Alle Ursachen, die ein HCC in einer Leberzirrhose (LZ) verursachen, können auch ohne Zirrhose zu einem HCC führen. Nach der relativen Häufigkeit kann man grob 3 Gruppen von Erkrankungen unterscheiden. 1. HCC, die selten ohne LZ entstehen (z. B. Virushepatitis, Alkoholabusus). 2. HCC, die häufiger auch ohne LZ entstehen (z. B. Alpha-1-Antitrypsin-Mangel, Hämochromatose, nichtalkoholische Fettlebererkrankung). 3. HCC, die grundsätzlich ohne LZ entstehen (z. B. Glykogenose Typ 1, Gebrauch oraler Kontrazeptiva/anaboler Steroide). In Fällen der Gruppen 1 und 2 war die notwendige zytotoxische Dosis der Noxe zum Erreichen einer LZ noch nicht erreicht, der karzinogene Effekt hingegen schon wirksam, möglicherweise begünstigt durch Ko-Karzinogene und Wirtsfaktoren. Karzinogene der Gruppe 3 verändern eher adaptativ den hepatozellulären Metabolismus ohne nennenswerte Zytotoxizität, können aber bei langfristiger Einwirkung dennoch zu HCC führen. Insbesondere in diesen Fällen entstehen die Karzinome oft über die Zwischenstufe des hepatozellulären Adenoms (Adenom-Karzinom-Sequenz).
Literatur
1.
Zurück zum Zitat Bannasch P (1996) Pathogenesis of hepatocellular carcinoma: sequential cellular, molecular, and metabolic changes. Prog Liver Dis 14: 161–197PubMed Bannasch P (1996) Pathogenesis of hepatocellular carcinoma: sequential cellular, molecular, and metabolic changes. Prog Liver Dis 14: 161–197PubMed
2.
Zurück zum Zitat Bianchi L (1993) Glycogen storage disease I and hepatocellular tumours. Eur J Pediatr 152: S63–S70PubMedCrossRef Bianchi L (1993) Glycogen storage disease I and hepatocellular tumours. Eur J Pediatr 152: S63–S70PubMedCrossRef
3.
Zurück zum Zitat Blanc JF, De Ledinghen V, Bernard PH et al. (2000) Increased incidence of HFE C282Y mutations in patients with iron overload and hepatocellular carcinoma developed in non-cirrhotic liver. J Hepatol 32: 805–811PubMedCrossRef Blanc JF, De Ledinghen V, Bernard PH et al. (2000) Increased incidence of HFE C282Y mutations in patients with iron overload and hepatocellular carcinoma developed in non-cirrhotic liver. J Hepatol 32: 805–811PubMedCrossRef
4.
Zurück zum Zitat Bralet MP, Degott C, Belghiti J, Terris B (1998) Prevalence of the haemochromatosis gene mutation in non-cirrhotic liver with hepatocellular carcinoma. J Hepatol 28: 740–741PubMedCrossRef Bralet MP, Degott C, Belghiti J, Terris B (1998) Prevalence of the haemochromatosis gene mutation in non-cirrhotic liver with hepatocellular carcinoma. J Hepatol 28: 740–741PubMedCrossRef
5.
Zurück zum Zitat Burri E, Steuerwald M, Cathomas G et al. (2006) Hepatocellular carcinoma in a liver-cell adenoma within a non-cirrhotic liver. Eur J Gastroenterol Hepatol 18: 437–441PubMedCrossRef Burri E, Steuerwald M, Cathomas G et al. (2006) Hepatocellular carcinoma in a liver-cell adenoma within a non-cirrhotic liver. Eur J Gastroenterol Hepatol 18: 437–441PubMedCrossRef
6.
Zurück zum Zitat Cattan S, Wendum D, Chazouilleres O et al. (2000) Hepatocellular carcinoma and focal hepatic glycogenosis after prolonged azathioprine therapy. Hum Pathol 31: 874–876PubMedCrossRef Cattan S, Wendum D, Chazouilleres O et al. (2000) Hepatocellular carcinoma and focal hepatic glycogenosis after prolonged azathioprine therapy. Hum Pathol 31: 874–876PubMedCrossRef
7.
Zurück zum Zitat Chen SC, Cummings OW, Hartley MP et al. (2006) Hepatocellular carcinoma occurring in a patient with Crohn’s disease treated with both azathioprine and infliximab. Dig Dis Sci 51: 952–955PubMedCrossRef Chen SC, Cummings OW, Hartley MP et al. (2006) Hepatocellular carcinoma occurring in a patient with Crohn’s disease treated with both azathioprine and infliximab. Dig Dis Sci 51: 952–955PubMedCrossRef
8.
Zurück zum Zitat Closset J, Veys I, Peny MO et al. (2000) Retrospective analysis of 29 patients surgically treated for hepatocellular adenoma or focal nodular hyperplasia. Hepatogastroenterology 47: 1382–1384PubMed Closset J, Veys I, Peny MO et al. (2000) Retrospective analysis of 29 patients surgically treated for hepatocellular adenoma or focal nodular hyperplasia. Hepatogastroenterology 47: 1382–1384PubMed
9.
Zurück zum Zitat Davila JA, Morgan RO, Shaib Y et al. (2005) Diabetes increases the risk of hepatocellular carcinoma in the United States: A population based case control study. Gut 54: 533–539PubMedCrossRef Davila JA, Morgan RO, Shaib Y et al. (2005) Diabetes increases the risk of hepatocellular carcinoma in the United States: A population based case control study. Gut 54: 533–539PubMedCrossRef
10.
Zurück zum Zitat Dombrowski F, Flaschka C, Klotz L et al. (2006) Hepatocellular neoplasms after intrahepatic transplantation of ovarian fragments into ovariectomized rats. Hepatology 43: 857–867PubMedCrossRef Dombrowski F, Flaschka C, Klotz L et al. (2006) Hepatocellular neoplasms after intrahepatic transplantation of ovarian fragments into ovariectomized rats. Hepatology 43: 857–867PubMedCrossRef
11.
Zurück zum Zitat Dombrowski F, Mathieu C, Evert M (2006) Hepatocellular neoplasms induced by low-number pancreatic islet transplants in autoimmune diabetic BB/Pfd rats. Cancer Res 66: 1833–1843PubMedCrossRef Dombrowski F, Mathieu C, Evert M (2006) Hepatocellular neoplasms induced by low-number pancreatic islet transplants in autoimmune diabetic BB/Pfd rats. Cancer Res 66: 1833–1843PubMedCrossRef
12.
Zurück zum Zitat Edmondson HA, Reynolds TB, Henderson B, Benton B (1977) Regression of liver cell adenomas associated with oral contraceptives. Ann Intern Med 86: 180–182PubMed Edmondson HA, Reynolds TB, Henderson B, Benton B (1977) Regression of liver cell adenomas associated with oral contraceptives. Ann Intern Med 86: 180–182PubMed
13.
Zurück zum Zitat El-Serag HB, Rudolph KL (2007) Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132: 2557–2576PubMedCrossRef El-Serag HB, Rudolph KL (2007) Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132: 2557–2576PubMedCrossRef
14.
Zurück zum Zitat El-Serag HB, Tran T, Everhart JE (2004) Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 126: 460–468PubMedCrossRef El-Serag HB, Tran T, Everhart JE (2004) Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 126: 460–468PubMedCrossRef
15.
Zurück zum Zitat Evert M, Schneider-Stock R, Dombrowski F (2005) Overexpression of fatty acid synthase in chemically and hormonally induced hepatocarcinogenesis of the rat. Lab Invest 85: 99–108PubMed Evert M, Schneider-Stock R, Dombrowski F (2005) Overexpression of fatty acid synthase in chemically and hormonally induced hepatocarcinogenesis of the rat. Lab Invest 85: 99–108PubMed
16.
Zurück zum Zitat Ferrell LD (1993) Hepatocellular carcinoma arising in a focus of multilobular adenoma. A case report. Am J Surg Path 17: 525–529PubMedCrossRef Ferrell LD (1993) Hepatocellular carcinoma arising in a focus of multilobular adenoma. A case report. Am J Surg Path 17: 525–529PubMedCrossRef
17.
Zurück zum Zitat Fischer G, Hartmann H, Droese M et al. (1986) Histochemical and immunohistochemical detection of putative preneoplastic liver foci in women after long-term use of oral contraceptives. Virchows Arch B Cell Pathol 50: 321–327CrossRef Fischer G, Hartmann H, Droese M et al. (1986) Histochemical and immunohistochemical detection of putative preneoplastic liver foci in women after long-term use of oral contraceptives. Virchows Arch B Cell Pathol 50: 321–327CrossRef
18.
Zurück zum Zitat Foster JH, Berman MM (1994) The malignant transformation of liver cell adenomas. Arch Surg 129: 712–717PubMed Foster JH, Berman MM (1994) The malignant transformation of liver cell adenomas. Arch Surg 129: 712–717PubMed
19.
Zurück zum Zitat Franco LM, Krishnamurthy V, Bali D et al. (2005) Hepatocellular carcinoma in glycogen storage diesease type Ia: A case series. J Inherit Metab Dis 28:153–162PubMedCrossRef Franco LM, Krishnamurthy V, Bali D et al. (2005) Hepatocellular carcinoma in glycogen storage diesease type Ia: A case series. J Inherit Metab Dis 28:153–162PubMedCrossRef
20.
Zurück zum Zitat Gordon SC, Reddy R, Livingstone AS et al. (1986) Resolution of a contraceptive-steroid-induced hepatic adenoma with subsequent evolution into hepatocellular carcinoma. Ann Intern Med 105: 547–549PubMed Gordon SC, Reddy R, Livingstone AS et al. (1986) Resolution of a contraceptive-steroid-induced hepatic adenoma with subsequent evolution into hepatocellular carcinoma. Ann Intern Med 105: 547–549PubMed
21.
Zurück zum Zitat Gyorffy EJ, Bredfeldt JE, Black WC (1989) Transformation of hepatic cell adenoma to hepatocellular carcinoma due to oral contraceptive use. Ann Intern Med 110: 489–490PubMed Gyorffy EJ, Bredfeldt JE, Black WC (1989) Transformation of hepatic cell adenoma to hepatocellular carcinoma due to oral contraceptive use. Ann Intern Med 110: 489–490PubMed
22.
Zurück zum Zitat Hai S, Kubo S, Shuto T et al. (2006) Hepatocellular carcinoma arising from nonalcoholic steatohepatitis: Report of two cases. Surg Today 36: 390–394PubMedCrossRef Hai S, Kubo S, Shuto T et al. (2006) Hepatocellular carcinoma arising from nonalcoholic steatohepatitis: Report of two cases. Surg Today 36: 390–394PubMedCrossRef
23.
Zurück zum Zitat Korula J, Yellin A, Kanel G et al. (1991) Hepatocellular carcinoma coexisting with hepatic adenoma. Incidental discovery after long-term oral contraceptive use. Western J Med 155: 416–418 Korula J, Yellin A, Kanel G et al. (1991) Hepatocellular carcinoma coexisting with hepatic adenoma. Incidental discovery after long-term oral contraceptive use. Western J Med 155: 416–418
24.
Zurück zum Zitat Kowdley KV (2004) Iron, hemochromatosis and hepatocellular carcinoma. Gastroenterology 127: S79–S86PubMedCrossRef Kowdley KV (2004) Iron, hemochromatosis and hepatocellular carcinoma. Gastroenterology 127: S79–S86PubMedCrossRef
25.
Zurück zum Zitat Lai MS, Hsieh MS, Chiu YH, Chen THH (2006) Type 2 diabetes and hepatocellular carcinoma: A cohort study in high prevalence area of hepatitis virus infection. Hepatology 43: 1295–1302PubMedCrossRef Lai MS, Hsieh MS, Chiu YH, Chen THH (2006) Type 2 diabetes and hepatocellular carcinoma: A cohort study in high prevalence area of hepatitis virus infection. Hepatology 43: 1295–1302PubMedCrossRef
26.
Zurück zum Zitat Libbrecht L, Craninx M, Nevens F et al. (2001) Predictive value of liver cell dysplasia for development of hepatocellular carcinoma in patients with non-cirrhotic and cirrhotic chronic viral hepatitis. Histopathology 39: 66–73PubMedCrossRef Libbrecht L, Craninx M, Nevens F et al. (2001) Predictive value of liver cell dysplasia for development of hepatocellular carcinoma in patients with non-cirrhotic and cirrhotic chronic viral hepatitis. Histopathology 39: 66–73PubMedCrossRef
27.
Zurück zum Zitat MacSween RNM, Burt AD, Portmann BC et al. (eds) (2002) Pathology of the liver. Harcourt, London MacSween RNM, Burt AD, Portmann BC et al. (eds) (2002) Pathology of the liver. Harcourt, London
28.
Zurück zum Zitat Nzeako U, Goodman Z, Ishak KG (1996) Hepatocellular carcinoma in cirrhotic and noncirrhotic livers. Am J Clin Pathol 105: 65–75PubMed Nzeako U, Goodman Z, Ishak KG (1996) Hepatocellular carcinoma in cirrhotic and noncirrhotic livers. Am J Clin Pathol 105: 65–75PubMed
29.
Zurück zum Zitat Ohata K, Hamasaki K, Toriyama K et al. (2003) Hepatic steatosis is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis c virus infection. Cancer 97: 3036–3043PubMedCrossRef Ohata K, Hamasaki K, Toriyama K et al. (2003) Hepatic steatosis is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis c virus infection. Cancer 97: 3036–3043PubMedCrossRef
30.
Zurück zum Zitat Okuda K, Nakashima T, Kojiro M et al. (1989) Hepatocellular carcinoma without cirrhosis in Japanese patients. Gastroenterology 97: 140–146PubMed Okuda K, Nakashima T, Kojiro M et al. (1989) Hepatocellular carcinoma without cirrhosis in Japanese patients. Gastroenterology 97: 140–146PubMed
31.
Zurück zum Zitat Okuda K, Tabor E (eds) (1997) Liver Cancer. Churchill-Livingstone, London Okuda K, Tabor E (eds) (1997) Liver Cancer. Churchill-Livingstone, London
32.
Zurück zum Zitat Regimbeau JM, Colombat M, Mognol P et al. (2004) Obesity and diabetes as a risk factor for hepatocellular carcinoma. Liver Transpl 10: S69–S73PubMedCrossRef Regimbeau JM, Colombat M, Mognol P et al. (2004) Obesity and diabetes as a risk factor for hepatocellular carcinoma. Liver Transpl 10: S69–S73PubMedCrossRef
33.
Zurück zum Zitat Su Q, Benner A, Hofmann WJ et al. (1997) Human hepatic preneoplasia: phenotypes and proliferation kinetics of foci and nodules of altered hepatocytes and their relationship to liver cell dysplasia. Virchows Arch 431: 291–406CrossRef Su Q, Benner A, Hofmann WJ et al. (1997) Human hepatic preneoplasia: phenotypes and proliferation kinetics of foci and nodules of altered hepatocytes and their relationship to liver cell dysplasia. Virchows Arch 431: 291–406CrossRef
34.
Zurück zum Zitat Tesluk H, Lawrie J (1981) Hepatocellular adenoma. Its transformation to carcinoma in a user of oral contraceptives. Arch Pathol Lab Med 105: 296–299PubMed Tesluk H, Lawrie J (1981) Hepatocellular adenoma. Its transformation to carcinoma in a user of oral contraceptives. Arch Pathol Lab Med 105: 296–299PubMed
35.
Zurück zum Zitat Trevisani F, D’Intino PE, Caraceni P et al. (1995) Etiologic factors and clinical presentation of hepatocellular carcinoma. Differences between cirrhotic and noncirrhotic Italian patients. Cancer 75: 2220–2232PubMedCrossRef Trevisani F, D’Intino PE, Caraceni P et al. (1995) Etiologic factors and clinical presentation of hepatocellular carcinoma. Differences between cirrhotic and noncirrhotic Italian patients. Cancer 75: 2220–2232PubMedCrossRef
36.
Zurück zum Zitat Turlin B, Juguet F, Moirand R et al. (1995) Increased liver iron stores in patients with hepatocellular carcinoma developed on a noncirrhotic liver. Hepatology 22: 446–450PubMed Turlin B, Juguet F, Moirand R et al. (1995) Increased liver iron stores in patients with hepatocellular carcinoma developed on a noncirrhotic liver. Hepatology 22: 446–450PubMed
37.
Zurück zum Zitat Van Roey G, Fevery J, van Steenbergen W (1999) Hepatocellular carcinoma in Belgium: clinical and virological characteristics of 154 consecutive cirrhotic and non-cirrhotic patients. Eur J Gastroenterol Hepatol 12: 61–66 Van Roey G, Fevery J, van Steenbergen W (1999) Hepatocellular carcinoma in Belgium: clinical and virological characteristics of 154 consecutive cirrhotic and non-cirrhotic patients. Eur J Gastroenterol Hepatol 12: 61–66
38.
Zurück zum Zitat Velazquez I, Alter BP (2004) Androgens and liver tumors: Fanconi’s anemia and Non-Fanconi’s conditions (2004) Am J Hematol 77: 257–267 Velazquez I, Alter BP (2004) Androgens and liver tumors: Fanconi’s anemia and Non-Fanconi’s conditions (2004) Am J Hematol 77: 257–267
39.
Zurück zum Zitat Yu MC, Yuan JM (2004) Environmental factors and risk for hepatocellular carcinoma. Gastroenterology 237: S72–S78CrossRef Yu MC, Yuan JM (2004) Environmental factors and risk for hepatocellular carcinoma. Gastroenterology 237: S72–S78CrossRef
40.
Zurück zum Zitat Zhou H, Ortiz-Pallardo ME, Ko Y, Fischer HP (2000) Is heterozygous alpha-1-antitrypsin deficiency type PIZ a risk factor for primary liver carcinoma? Cancer 88: 2668–2676PubMedCrossRef Zhou H, Ortiz-Pallardo ME, Ko Y, Fischer HP (2000) Is heterozygous alpha-1-antitrypsin deficiency type PIZ a risk factor for primary liver carcinoma? Cancer 88: 2668–2676PubMedCrossRef
Metadaten
Titel
Hepatozelluläre Karzinome in der nichtzirrhotischen Leber
verfasst von
M. Evert
Prof. Dr. F. Dombrowski
Publikationsdatum
01.02.2008
Verlag
Springer-Verlag
Erschienen in
Die Pathologie / Ausgabe 1/2008
Print ISSN: 2731-7188
Elektronische ISSN: 2731-7196
DOI
https://doi.org/10.1007/s00292-007-0953-3

Weitere Artikel der Ausgabe 1/2008

Der Pathologe 1/2008 Zur Ausgabe

Schwerpunkt: Leberpathologie

Maß und Zahl in der Hepatopathologie

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.